City Therapeutics Secures $99.5M Series B Financing to Advance RNAi Programs Targeting Coagulation Factor XI and Ophthalmic Disease

Note:This article does not constitute any investment advice or recommendations; please refer to official/company announcements for authoritative information.This article is for informational purposes only regarding medications related to medical and health care. It does not constitute a recommendation for treatment plans (if any), nor does it represent the platform’s position.Authorization is required for any article reposting.

PharmCube DataMonitoring shows: On June 8, 2026, City Therapeutics, Inc., an emerging small-molecule RNA interference (RNAi) drug company, completed$99.5 millionSeries B Financing.

This round of financing is led by new investorsViking Led by Global Investors and Sofinnova Investments, with participation from Casdin Capital and NYBC Ventures; existing investors ARCH Venture Partners, Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital,Regeneron Ventures, AN Ventures and other undisclosed investors participated jointly.

The company has recently launchedCITY-FXIPhase I clinical trial, the product targets coagulation factor XI (FXI) for the treatment of thromboembolic diseases;

Simultaneously announcedCITY-RBP4positive preclinical data, a potential first-in-class RNAi therapy for the treatment of ophthalmic diseasesStargardt disease/Juvenile macular degeneration。

The company plans to advance two projects, including CITY-RBP4, to the clinical stage by the end of 2026.

Since completing its Series A financing two years ago, City Therapeutics has achieved several key milestones, including advancing CITY-FXI into clinical development and collaborating with ophthalmologyBausch + Lomband BiogenReached a major strategic partnership.

City Therapeutics’ pipeline is robust, with additional projects expected to be in development.

City Therapeutics Co-Founder and Executive ChairmanJohn Maraganore（Founding CEO / Alnylam Pharmaceuticals）; Andy Orth, CEO of City Therapeutics (formerChief Commercial Officer, Krystal Biotech）。

Dr. Baisong Mei, a renowned Chinese-American scientist, serves as the CMO; he is an early graduate of Bengbu Medical University. Previously atHeld executive positions at companies such as Editas Medicine and Sanofi.

References:

Pharmaceutical Circle Data;

https://www.citytx.com/news/city-therapeutics-announces-99-5-million-series-b-financing-to-advance-next-generation-rnai-therapeutics；

https://www.sec.gov/Archives/edgar/data；

https://www.businesswire.com；

https://lifescivoice.com；

https://www.globenewswire.com/news-release；

https://www.citytx.com/baisong-mei；

Wait.